100% Quality Guarantee
PhD-Level Technical Support
Key Features

Icrucumab Biosimilar (FLT1) Antibody (HDBS0116)

SKU HDBS0116
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein FLT1
Reactivity Human
Host Species Humanized
Isotype IgG1
€431

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Icrucumab Biosimilar (FLT1) Antibody (HDBS0116)

The iCrucumab Biosimilar FLT1 Antibody is a cutting-edge tool for researchers studying the FLT1 protein, a receptor essential in angiogenesis and vascular development. This antibody, derived from innovative biosimilar technology, is highly specific and sensitive in detecting FLT1 in various samples, making it ideal for use in studies related to cancer, cardiovascular diseases, and other angiogenesis-related conditions.FLT1, also known as the vascular endothelial growth factor receptor 1 (VEGFR1), is a key player in the regulation of blood vessel formation and has been implicated in tumor growth and metastasis. By targeting FLT1 with the iCrucumab Biosimilar FLT1 Antibody, researchers can gain insights into the role of this receptor in disease progression and potentially identify new therapeutic strategies for combating diseases like cancer.

This antibody is rigorously tested and validated for use in various applications, including Western blotting, immunohistochemistry, and flow cytometry, ensuring accurate and reliable results in experimental settings. With its unparalleled specificity and versatility, the iCrucumab Biosimilar Anti-FLT1 Antibody is a valuable asset for researchers seeking to unravel the complexities of angiogenesis and develop targeted therapies for FLT1-associated diseases.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose